A method for increasing CD8+ cytotoxic T cell reponses and for treating multiple sclerosis

Details for Australian Patent Application No. 2004281817 (hide)

Owner Baylor College of Medicine

Inventors Zang, Ying C. Q.

Agent Shelston IP

Pub. Number AU-B-2004281817

PCT Pub. Number WO2005/037309

Priority 60/512,212 17.10.03 US

Filing date 18 October 2004

Wipo publication date 28 April 2005

Acceptance publication date 22 July 2010

International Classifications

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

C12N 5/07 (2010.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Animal cells or tissues

Event Publications

15 June 2006 Section 223 Application Allowed

  Baylor College of Medicine The time in which to enter the National Phase has been extended to 17 Jun 2006. Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000 Extensions of Time, Section 223

22 June 2006 PCT application entered the National Phase

  PCT publication WO2005/037309 Priority application(s): WO2005/037309

22 July 2010 Application Accepted

  Published as AU-B-2004281817

18 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004281829-Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents

2004281816-Chromium oxide compositions containing zinc, their preparation, and their use as catalysts and catalyst precursors